Trackmaster
About Trackmaster
Trackmaster, the next-generation Everolimus-Eluting Coronary Stent System, is designed for exceptional flexibility, controlled drug release, and superior clinical outcomes. Engineered with ultra-thin strut technology, Trackmaster ensures seamless vessel adaptability, reduced arterial injury, and optimized endothelialization.
Manufactured at Kamal Medtech’s state-of-the-art 50,000 sq. ft. facility, Trackmaster meets global healthcare standards, offering unmatched safety and effectiveness for complex coronary interventions.
01
Optimized Drug Release Profile
Controlled Everolimus release up to 50 days, ensuring gradual healing and minimal restenosis risk.
02
Bioresorvable Polymer Coating
Fully degrades through hydrolysis and enzymatic degradation, naturally excreting from the body as CO₂ and H₂O.
03
Ultra-Thin Strut Design (65µm)
Enhances stent flexibility, reducing vessel trauma and improving crossability in complex anatomies.
04
Exceptional Radial Strength & Precision Placement
Ensures uniform vessel support, maintaining integrity without foreshortening or recoil.
05
Engineered for Complex Lesions
Designed for superior deliverability in tortuous vessels, offering seamless tracking and expansion.
Happiness Starts With Health
Polymers
Biodegradable polymers blend, act as a binding factor for the drug. The unique and validated formulation help drug release in a controlled fashion.
PTCA Balloon Catheter
- Drug coated stent is mounted on the balloon portion of PTCA balloon Catheter, the latter assists in stent positioning & dilatation. The Ultra-low profile, excellent crossability and flexible tip of PTCA balloon Catheter help entire stent system to achieve its expected clinical outcomes.
Unique stent design together with proven efficacy of Everolimus drug & Biodegradable polymers resulted into Trackmaster with excellent safety & efficacy profile

Cobalt Chromium Stent Platform
Meticulously laser cut Cobalt Chromium Stent proves to be an ideal platform for DES, contributing to high flexibility, conformability, unidirectional expansion with no edge flaring and minimum recoil.

Everolimus Drug
The cytostatic drug, inhibits blood vessel restenosis by limiting the proliferation of smooth muscle cells
Stent Specification
| Design: | Open Cell Stent Design | ||
|---|---|---|---|
| Material: | Cobalt Chromium (CoCr) L605 | ||
| Length (mm): | 8, 13, 16, 20, 24, 28, 32, 36, 40, 43 8 47 | ||
| Diameter (mm): | 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00 & 4.50 | ||
| Strut Dimensions: | Thickness 60-65 um | Strut 70 µm | Connectors 50 µm | ||
| Nominal Pressure (NP): | 9 atm | ||
| Rated Burst Pressure (RBP): | 16 atm | ||
| Foreshortening: | Nearly Zero | ||
| Recoil: | <_5% | ||
| Crossing Profile: | Nearly 100 mm | ||
| Min. Guidewire Diameter: | 0.014” | ||
| Min. Guiding Catheter I.D.: | 5 Fr Compatible | ||
| Radial Strength: | Excellent | ||
| Flexibility: | Excellent | ||
Ordering Information
| Dia(mm) | 8 | 13 | 16 | 20 | 24 | 28 | 32 | 36 | 40 | 43 | 47 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.00 | TR20008 | TR20013 | TR20016 | TR20020 | TR20024 | TR20028 | TR20032 | TR20036 | TR20040 | TR20043 | TR20047 |
| 225 | TR22508 | TR22513 | TR22516 | TR22520 | TR22524 | TR22528 | TR22532 | TR22536 | TR22540 | TR22543 | TR22547 |
| 250 | TR25008 | TR25013 | TR25016 | TR25020 | TR25024 | TR25028 | TR25032 | TR25036 | TR25040 | TR25043 | TR25047 |
| 2.75 | TR27508 | TR27513 | TR27516 | TR27520 | TR27524 | TR27528 | TR27532 | TR27536 | TR27540 | TR27543 | TR27547 |
| 3.00 | TR30008 | TR30013 | TR30016 | TR30020 | TR30024 | TR30028 | TR30032 | TR30036 | TR30040 | TR30043 | TR30047 |
| 350 | TR35008 | TR35013 | TR35016 | TR35020 | TR35024 | TR35028 | TR35032 | TR35036 | TR35040 | TR35043 | TR35047 |
| 4.00 | TR40008 | TR40013 | TR40016 | TR40020 | TR40024 | TR40028 | TR40032 | TR40036 | TR40040 | TR40043 | TR40047 |
| 450 | TR45008 | TR45013 | TR45016 | TR45020 | TR45024 | TR45028 | TR45032 | TR45036 | TR45040 | TR45043 | TR45047 |